Global Asthma Biologics Market to Hit USD 28.20 Bn by 2035 | CAGR 12.34%

Read more about this report- Global Asthma Biologics Market to Hit USD 28.20 Bn by 2035 | CAGR 12.34%

• The Asthma Biologics Market is valued at USD 7.84 billion in 2024.
• The Asthma Biologics Market will achieve USD 28.20 billion by 2035 through a projected 12.34% CAGR from 2025 to 2035.
• The growing prevalence of asthma, the growing awareness of personalized forms of treatment, and the increasing use of biologic therapy by severe asthma patients all contribute to the significant growth of the Asthma Biologics Market. Increased efficacy, targeted therapies, and decreased side effects over conventional therapy are also contributing to market uptake in a wide range of patients. Also, government programs and health awareness programs that focus on respiratory health are helping to drive positive market changes.
• Asthma type can also be used to segment the market, such as severe eosinophilic asthma, allergic asthma, and other asthma phenotypes. Severe eosinophilic asthma is the market leader by virtue of its high unmet medical need and sensitivity to biologic treatments. The increasing rate of allergic asthma and the growing number of specific biologic treatments are greatly increasing the usage of allergic asthma.
• By drug class, the market can be separated into monoclonal antibodies (mAbs) and other biologics. Monoclonal antibodies dominate the market because they are already tested as effective in curbing symptoms of severe asthma and also decreasing exacerbations. Another factor that is making biologics more popular among patients and health care providers is innovative formulations with better safety profiles.
• The market is further classified based on route of administration, i.e., subcutaneous injections and intravenous infusions. Subcutaneous is becoming the preferred route of administration owing to its convenience, ease, and at-home treatment, but intravenous administration is mainly applied in hospital and clinical environments to treat serious cases of the disease that require monitored administration.
• Hospitals and clinics, specialty care centers, and home healthcare services are the end-users of asthma biologics. Hospitals and clinics continue to be primary consumers because they handle severe cases of asthma, whereas specialty care centers are becoming more and more involved in the provision of biologic therapies under expert guidance. The popularity of home healthcare services and patient education about self-administration is increasing access to biologics among patients with persistent asthma that persists.
• Market growth is also driven by rising disposable income, development of health care infrastructure, and reimbursement in developed and emerging markets. Continuous product development, next-generation biologics, biosimilars, and combination therapy are improving treatment outcomes and increasing the patient base.
• The market is geographically distributed in North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The market is mainly dominated by North America due to the high rate of disease awareness, well-developed health systems, and good R&D. Asia Pacific will register the greatest growth rate due to the increasing prevalence of asthma, urbanization, increasing access to healthcare, and government programs encouraging high-tech therapies.
• Among the players that may influence the development of the modern asthma biologics market, there are Amgen Inc., AstraZeneca, Novartis International AG, GlaxoSmithKline (GSK), and other entities. Strategic product introductions and next-generation biologics, sustainable patient-friendly formulations, and multi-channel distribution are other areas that these companies are emphasizing to reinforce their market presence and respond to changing patient needs.